$200M investment to advance clinical programs for Ambrx

Ambrx, Astellas, BeiGene, BioPharma, BlackRock, Bristol-Myers Squibb, cardiovascular disease, Cormorant Asset Management, Daily, Fidelity Management and Research, HBM Healthcare Investments, News, Oncology, Pharma, San Diego, SYN, Top Story / November 23, 2020

The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.